全文获取类型
收费全文 | 153篇 |
免费 | 11篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 3篇 |
妇产科学 | 1篇 |
基础医学 | 20篇 |
口腔科学 | 11篇 |
临床医学 | 16篇 |
内科学 | 35篇 |
皮肤病学 | 8篇 |
神经病学 | 16篇 |
特种医学 | 7篇 |
外科学 | 12篇 |
预防医学 | 7篇 |
眼科学 | 2篇 |
药学 | 13篇 |
中国医学 | 1篇 |
肿瘤学 | 16篇 |
出版年
2023年 | 1篇 |
2022年 | 5篇 |
2021年 | 5篇 |
2020年 | 6篇 |
2019年 | 8篇 |
2018年 | 2篇 |
2017年 | 6篇 |
2016年 | 4篇 |
2015年 | 4篇 |
2014年 | 2篇 |
2013年 | 14篇 |
2012年 | 14篇 |
2011年 | 23篇 |
2010年 | 10篇 |
2009年 | 12篇 |
2008年 | 12篇 |
2007年 | 11篇 |
2006年 | 9篇 |
2005年 | 12篇 |
2004年 | 5篇 |
2003年 | 2篇 |
2002年 | 1篇 |
排序方式: 共有168条查询结果,搜索用时 515 毫秒
81.
ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease 总被引:10,自引:0,他引:10
Wollmer MA Streffer JR Lütjohann D Tsolaki M Iakovidou V Hegi T Pasch T Jung HH Bergmann Kv Nitsch RM Hock C Papassotiropoulos A 《Neurobiology of aging》2003,24(3):421-426
Increased formation of the beta-amyloid peptide (Abeta) is a central event in the pathogenesis of Alzheimer's disease (AD). High cellular cholesterol load promotes Abeta formation. The ATP-binding cassette transporter A1 (ABCA1) mediates cholesterol efflux from cells. We hypothesized that genetic variability in ABCA1 may influence cholesterol metabolism in the central nervous system (CNS) and, thus, interfere with the development of AD. Healthy elderly carriers of the A allele of a non-synonymous (R219K) single nucleotide polymorphism (SNP) in the ABCA1 gene (rs2234884) had on average 33% lower total cholesterol in cerebrospinal fluid (CSF) than non-carriers. In 169 patients with late onset, sporadic AD, this allele was associated with delayed age at onset of the disease by 1.7 years on average. Rs2234884 and another non-synonymous SNP (R1587K) in ABCA1 (rs2234886) failed to show significant association with the risk for AD. We conclude that genetic variability of ABCA1 influences the development of AD, possibly by interfering with CNS cholesterol homeostasis. 相似文献
82.
83.
Mary Geitona Magdalini Hatzikou Zoi Hatzistamatiou Aggeliki Anastasiadou T D Theodoratou 《Cost effectiveness and resource allocation : C/E》2007,5(1):1-7
Background
Measurement of individuals' costs and outcomes in randomized trials allows uncertainty about cost effectiveness to be quantified. Uncertainty is expressed as probabilities that an intervention is cost effective, and confidence intervals of incremental cost effectiveness ratios. Randomizing clusters instead of individuals tends to increase uncertainty but such data are often analysed incorrectly in published studies.Methods
We used data from a cluster randomized trial to demonstrate five appropriate analytic methods: 1) joint modeling of costs and effects with two-stage non-parametric bootstrap sampling of clusters then individuals, 2) joint modeling of costs and effects with Bayesian hierarchical models and 3) linear regression of net benefits at different willingness to pay levels using a) least squares regression with Huber-White robust adjustment of errors, b) a least squares hierarchical model and c) a Bayesian hierarchical model.Results
All five methods produced similar results, with greater uncertainty than if cluster randomization was not accounted for.Conclusion
Cost effectiveness analyses alongside cluster randomized trials need to account for study design. Several theoretically coherent methods can be implemented with common statistical software. 相似文献84.
Matrix metalloproteinase (MMP)-11, or Stromelysin 3, is a particular member of MMP family, a group of zinc-dependent endopeptidases involved in matrix degradation and tissue remodeling. Despite intense efforts since its first characterization 15 years ago, its role and target substrates in different diseases remain largely unknown. While mice with MMP-11 deficiency display no particular phenotype, analysis of different tumorigenesis models with these mice lead to the conclusion that MMP-11 promotes tumor development. In contrast with other MMPs, MMP-11 is unable to degrade any major extracellular matrix component and unlike most of other MMPs that are secreted as inactive proenzymes and activated extracellularly, MMP-11 is secreted under active form. MMP-11 may thus play a unique role in tissue remodeling processes, including those associated with tumor progression. Although MMP-11 and other MMPs have been considered as promising targets to combat cancer, a first series of clinical trials using broad-spectrum MMP inhibitors have not led to significant therapeutic benefits. These disappointing results highlight the need for better understanding of the exact role played by each MMP during the different stages of tumor progression. Among the different strategies to fill this gap, highly specific MMP inhibitors would be of great value. This review provides an update on the selectivity profile of phosphinic MMP-11 synthetic inhibitors developed and discusses the opportunities and limitations to identify inhibitors able to fully discriminate MMP-11 from the other MMPs. 相似文献
85.
86.
Gavriatopoulou Maria Terpos Evangelos Kastritis Efstathios Briasoulis Alexandros Gumeni Sentiljana Ntanasis-Stathopoulos Ioannis Sklirou Aimilia D. Malandrakis Panagiotis Eleutherakis-Papaiakovou Evangelos Migkou Magdalini Trougakos Ioannis P. Dimopoulos Meletios A. 《Clinical and experimental medicine》2022,22(2):319-323
Clinical and Experimental Medicine - Vaccination against SARS-CoV-2 is considered as the most important preventive strategy against COVID-19, but its efficacy in patients with hematological... 相似文献
87.
88.
89.
90.